NeuroMetrix Q4 2022 Earnings Report

NeuroMetrix EPS Results

• Actual EPS: -$0.72
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

NeuroMetrix Revenue Results

• Actual Revenue: $1.85 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

NeuroMetrix Announcement Details

• Quarter: Q4 2022
• Date: 2/23/2023
• Time: N/A

NeuroMetrix (NASDAQ:NURO), a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.